Login
Home
Charts
Search
Watchlist
Products

Tatva Chintan Pharma Chem Ltd

TATVA·NSE
₹1,744.20-0.97%Tue, 22 Sept '26 15:58
Industry:Speciality Chemicals
Indices:

Tatva Chintan Pharma Chem Ltd

TATVA
NSE
₹1,744.20
-0.97%
|Tue, 22 Sept '26 15:58
SOICxStockScans Reports
Industry
Speciality Chemicals
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹4,070Cr
Close
Close Price
₹1,739.90
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
79.19
PS
Price To Sales
7.32
Revenue
Revenue
₹556Cr
Rev Gr TTM
Revenue Growth TTM
41.09%
PAT Gr TTM
PAT Growth TTM
617.74%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9784981058386108117124131134167
Growth YoY
Revenue Growth YoY%
7.3-30.2-21.1-7.8-13.62.09.810.848.052.924.443.0
Expenses
ExpensesCr
76738393787999100101106106135
Operating Profit
Operating ProfitCr
201116136791722252832
OPM
OPM%
20.913.115.912.06.78.28.314.818.019.421.019.3
Other Income
Other IncomeCr
115100111201
Interest Expense
Interest ExpenseCr
300000001012
Depreciation
DepreciationCr
77677779991011
PBT
PBTCr
115147-102914181721
Tax
TaxCr
324200124265
PAT
PATCr
83105-101710151016
Growth YoY
PAT Growth YoY%
9.4-70.2-43.3-45.2-108.5-96.0-89.327.61,603.010,735.7901.9140.3
NPM
NPM%
8.14.19.84.9-0.80.20.95.78.011.67.79.6
EPS
EPS₹
3.41.54.12.2-0.30.10.42.84.26.54.46.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9784981058386108117124131134167
Growth YoY
Revenue Growth YoY%
7.3-30.2-21.1-7.8-13.62.09.810.848.052.924.443.0
Expenses
ExpensesCr
76738393787999100101106106135
Operating Profit
Operating ProfitCr
201116136791722252832
OPM
OPM%
20.913.115.912.06.78.28.314.818.019.421.019.3
Other Income
Other IncomeCr
115100111201
Interest Expense
Interest ExpenseCr
300000001012
Depreciation
DepreciationCr
77677779991011
PBT
PBTCr
115147-102914181721
Tax
TaxCr
324200124265
PAT
PATCr
83105-101710151016
Growth YoY
PAT Growth YoY%
9.4-70.2-43.3-45.2-108.5-96.0-89.327.61,603.010,735.7901.9140.3
NPM
NPM%
8.14.19.84.9-0.80.20.95.78.011.67.79.6
EPS
EPS₹
3.41.54.12.2-0.30.10.42.84.26.54.46.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
136206263300434424394383506556
Growth
Revenue Growth%
51.927.614.144.4-2.3-7.1-2.732.241.1
Expenses
ExpensesCr
113173208234325363325349413448
Operating Profit
Operating ProfitCr
2334556610861683493108
OPM
OPM%
16.916.420.922.125.014.317.38.918.419.4
Other Income
Other IncomeCr
1115928244
Interest Expense
Interest ExpenseCr
2444587135
Depreciation
DepreciationCr
345781026283738
PBT
PBTCr
19274861104454485769
Tax
TaxCr
771088-11321518
PAT
PATCr
1221385296453064251
Growth
PAT Growth%
67.284.038.383.5-52.6-33.3-81.2636.1617.7
NPM
NPM%
9.110.014.417.422.110.77.71.58.39.2
EPS
EPS₹
6.110.218.826.044.620.513.32.418.022.0
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
136206263300434424394383506556
Growth
Revenue Growth%
51.927.614.144.4-2.3-7.1-2.732.241.1
Expenses
ExpensesCr
113173208234325363325349413448
Operating Profit
Operating ProfitCr
2334556610861683493108
OPM
OPM%
16.916.420.922.125.014.317.38.918.419.4
Other Income
Other IncomeCr
1115928244
Interest Expense
Interest ExpenseCr
2444587135
Depreciation
DepreciationCr
345781026283738
PBT
PBTCr
19274861104454485769
Tax
TaxCr
771088-11321518
PAT
PATCr
1221385296453064251
Growth
PAT Growth%
67.284.038.383.5-52.6-33.3-81.2636.1617.7
NPM
NPM%
9.110.014.417.422.110.77.71.58.39.2
EPS
EPS₹
6.110.218.826.044.620.513.32.418.022.0

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
888202222232323
Reserves
ReservesCr
5172110146451493714715758
Current Liabilities
Current LiabilitiesCr
6373881181712398096213
Non Current Liabilities
Non Current LiabilitiesCr
22354431145219
Total Liabilities
Total LiabilitiesCr
1441882493156587598198361,004
Current Assets
Current AssetsCr
77114133184436312298265350
Non Current Assets
Non Current AssetsCr
6773116131222447521571654
Total Assets
Total AssetsCr
1441882493156587598198361,004
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
888202222232323
Reserves
ReservesCr
5172110146451493714715758
Current Liabilities
Current LiabilitiesCr
6373881181712398096213
Non Current Liabilities
Non Current LiabilitiesCr
22354431145219
Total Liabilities
Total LiabilitiesCr
1441882493156587598198361,004
Current Assets
Current AssetsCr
77114133184436312298265350
Non Current Assets
Non Current AssetsCr
6773116131222447521571654
Total Assets
Total AssetsCr
1441882493156587598198361,004

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
13725202028982531
Investing Cash Flow
Investing Cash FlowCr
-30-17-40-21-197-101-121-65-116
Financing Cash Flow
Financing Cash FlowCr
71710-523538311779
Net Cash Flow
Net Cash FlowCr
-108-5-659-368-24-5
Free Cash Flow
Free Cash FlowCr
-18-2-23-1-69-175-30-51-82
CFO To PAT
CFO To PAT%
102.435.867.037.721.361.1323.0433.674.9
CFO To EBITDA
CFO To EBITDA%
54.921.846.129.618.845.9143.872.433.8
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
13725202028982531
Investing Cash Flow
Investing Cash FlowCr
-30-17-40-21-197-101-121-65-116
Financing Cash Flow
Financing Cash FlowCr
71710-523538311779
Net Cash Flow
Net Cash FlowCr
-108-5-659-368-24-5
Free Cash Flow
Free Cash FlowCr
-18-2-23-1-69-175-30-51-82
CFO To PAT
CFO To PAT%
102.435.867.037.721.361.1323.0433.674.9
CFO To EBITDA
CFO To EBITDA%
54.921.846.129.618.845.9143.872.433.8

Ratios

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,1153,6952,5251,5882,4584,070
Price To Earnings
Price To Earnings
53.481.283.2278.358.579.2
Price To Sales
Price To Sales
11.88.76.44.24.97.3
Price To Book
Price To Book
10.87.23.42.13.15.2
EV To EBITDA
EV To EBITDA
46.763.136.747.127.639.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
38.737.740.340.644.436.841.934.441.841.8
OPM
OPM%
16.916.420.922.125.014.317.38.918.419.4
NPM
NPM%
9.110.014.417.422.110.77.71.58.39.2
ROCE
ROCE%
19.320.526.225.318.47.86.71.16.66.6
ROE
ROE%
20.825.832.131.520.38.84.10.85.45.4
ROA
ROA%
8.611.015.216.614.66.03.70.74.24.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,1153,6952,5251,5882,4584,070
Price To Earnings
Price To Earnings
53.481.283.2278.358.579.2
Price To Sales
Price To Sales
11.88.76.44.24.97.3
Price To Book
Price To Book
10.87.23.42.13.15.2
EV To EBITDA
EV To EBITDA
46.763.136.747.127.639.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
38.737.740.340.644.436.841.934.441.841.8
OPM
OPM%
16.916.420.922.125.014.317.38.918.419.4
NPM
NPM%
9.110.014.417.422.110.77.71.58.39.2
ROCE
ROCE%
19.320.526.225.318.47.86.71.16.66.6
ROE
ROE%
20.825.832.131.520.38.84.10.85.45.4
ROA
ROA%
8.611.015.216.614.66.03.70.74.24.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Tatva Chintan Pharma Chem Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/r1676l6n0c7f57tz1wjt567c.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/spbxrsc6ceof130idqadxg6l.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/9nli176xgf6pgouu6o7200qv.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/es26upotkhwfi0e4pufbecjj.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/if5zbop2ig9x29iaa5blc7a4.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/c8qrs6ieobexv90v68din1ev.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/mbh9ucs7lzo9jsfot04epgda.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/o1y8zcwb33ludu97haos6t19.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/rvxq4mxk295i27t650loa3is.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/83qkbp1h5x8om69ks9u239hh.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/c5k3eupizn2k6n1jkepntmx9.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/lhx4wwyixhwouok77ookgy3j.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/d35xipu799f3g4031sq7i7cw.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/8g027hvhk3j2un821n6gz38a.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/n998a4cr87nb9n4jozq6qqp0.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/885tehy1otmbkdloy7inq1e2.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/yv1lfa92bxqaij3kcpxz4hbb.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/q0bag2nx09piaps0x0iluazl.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/5g9trcvi8cnajgp2tzfqfkxd.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/h0591crikd6vwok92i6v1ekz.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/fau1qrwlym6gchmurmxrz02l.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/se5fcpp5bqw8lecg4rv9bjns.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/3koesr2mdf9q054ohgio2oh7.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/7rq3jqyqz1g9wq3nzn8l7xsq.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/ppvrjil1w7w1a6t27ke3miyw.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/jasathhaot6dom8r8cwv88xt.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/vxr4u18cdv5485dauithp1ys.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/vwdi4sjpsr2efsx0axli3qdm.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/keg95gg2irjapsnmnkh7ntev.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/ramqfugz9aapcr55vy7wcslg.pdf

Concall Transcript Summaries — Tatva Chintan Pharma Chem Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202606/r1676l6n0c7f57tz1wjt567c.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202603/spbxrsc6ceof130idqadxg6l.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202512/9nli176xgf6pgouu6o7200qv.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202509/es26upotkhwfi0e4pufbecjj.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202506/if5zbop2ig9x29iaa5blc7a4.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202503/c8qrs6ieobexv90v68din1ev.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202412/mbh9ucs7lzo9jsfot04epgda.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3ATATVA/transcript-notes/202409/o1y8zcwb33ludu97haos6t19.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies